STOCKHOLM–(BUSINESS WIRE)–Regulatory News:
A Chinese study of infants with colic shows that babies given Lactobacillus reuteri Protectis cry significantly less compared to babies given placebo.
The newly published study is the fifth positive colic study with Lactobacillus reuteri Protectis and the results confirm the positive results of earlier studies.
100 per cent treatment success
Treatment success was observed in all infants supplemented by Lactobacillus reuteri Protectis while it was seen in barely 16 per cent of the placebo group. In addition, the study showed 100 per cent parent satisfaction in the Lactobacillus reuteri Protectis group, while barely 16 percent among parents of children in the placebo group reported treatment satisfaction. 42 infants were included in the study.
The study was published online in Antonie van Leeuwenhoek 16 April 2015. More information on colic, study details and previous colic studies with Lactobacillus reuteri Protectis is found through the attached links.
“With this study – the fifth independent, positive study with Lactobacillus reuteri Protectis on colic – we further strengthen our position in the paediatric field. Furthermore, it is valuable that we now also have strong data in this field from a study conducted in China”, says Peter Rothschild, President, BioGaia (STO:BIOGB).
Latest press releases from BioGaia
2015-04-08 Notice to attend the Annual General Meeting of BioGaia AB
2015-03-26 BioGaia subsidiary IBT starts trial already this year
2015-03-23 BioGaia signs exclusive agreement for oral health products in Mexico
BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 27 April 2015, 08:00 am CET.
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
This information was brought to you by Cision http://news.cision.com
Source: Business Wire Health